Anuh Pharma Limited — PPTs, 13-02-2026: Investor Presentation

Anuh Pharma showed strong Q3 FY26 performance, with revenue up 6% quarter-on-quarter to ₹197.18 Cr. EBITDA jumped 62.6% to ₹20.91 Cr, and profit after tax rose 76.7% to ₹13.45 Cr. For the first nine months of FY26, revenue increased 22.9% year-on-year to ₹569.54 Cr. However, 9M EBITDA declined 5.6% to ₹47.45 Cr and PAT fell 15.8% to ₹29.36 Cr, though management notes margin recovery is underway. Exports now contribute 45% of 9M revenue, highlighting strong global demand.

Strategic focus includes operational excellence, expanded capacity (now 2400 MTPA), and solar energy investments for cost savings and sustainability. The company successfully completed a USFDA inspection in February 2026 with zero observations, underscoring its quality. Management anticipates good demand and pricing trends, expecting 15-16% annual growth driven by higher utilization, efficiencies, and exploring inorganic growth opportunities to strengthen its product portfolio, particularly in lifestyle drugs.